Dietary supplement many not lower prostate cancer risk

November 04, 2003

COLUMBUS, Ohio - A tomato a day may help keep prostate cancer at bay -- but a widely used dietary supplement derived from tomatoes may not be sufficient. That's the conclusion of the first animal study comparing the cancer-preventing potential of tomato products to that of lycopene, a substance extracted from tomatoes and taken by many men in hopes of warding off prostate cancer.

Research by scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and their colleagues showed that rats with prostate cancer survived longer when fed a diet that included whole tomato products but not when fed the same diet plus lycopene. The effect was most apparent when the animals' food intake was modestly restricted. The study was published in the Nov. 4 issue of the Journal of the National Cancer Institute.

"Our findings strongly suggest that risks of poor dietary habits cannot be reversed simply by taking a pill," says study co-author Steven K. Clinton, associate professor of hematology and oncology and of human nutrition. "We shouldn't expect easy solutions to complex problems. We must focus more on choosing a variety of healthy foods, exercising and watching our weight."

A number of earlier studies have suggested that eating tomatoes and tomato products such as sauce, paste and soup is associated with a lower prostate-cancer risk. Scientists proposed that lycopene, a potent antioxidant and the substance that makes tomatoes red, gives the fruit its anti-cancer properties.

Clinton and his colleagues first separated 194 rats with prostate cancer into three groups. A control group was fed a balanced diet containing no detectable lycopene. The second group received the control diet plus lycopene, and a third group received the control diet mixed with tomato powder made from tomato paste that included seeds and skins.

Additionally, each group was subdivided into an energy-restricted group and an energy-unrestricted group. Animals in the unrestricted group received as much food as they wanted; energy-restricted animals received 20 percent less food than the unrestricted group. The experiment lasted about 14 months.

Rats in the tomato-fed, energy-unrestricted group showed a longer prostate-cancer free survival compared to controls. Their risk of dying from prostate cancer dropped by 26 percent. Animals in the tomato-fed, energy-restricted group fared even better, showing a 32 percent drop in risk. No benefit from lycopene alone was seen in either the energy-restricted or unrestricted groups.

"Our study does not say that lycopene is useless," Clinton says. "Instead it suggests that if we want the health benefits of tomatoes, we should eat tomatoes or tomato products and not rely on lycopene supplements alone."

Along with Clinton, John W. Erdman, Jr., professor of nutritional sciences, University of Illinois, Urbana-Champaign; Thomas W.-M. Boileau, post doctoral fellow; Zhiming Liao, research scientist; Sunny Kim, statistician; Stanley A. Lemeshow, professor of public health and director, Biostatistics Program, all from Ohio State, also worked on the project.
-end-
Funding from the National Cancer Institute and The Ohio State University Comprehensive Cancer Center supported this research.

Ohio State University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.